

**The following content was supplied by the authors as supporting material and has not been copy-edited or verified by JBJS.**

**Appendix I** Summary of Results from Multiple Randomized Clinical Trials Comparing Warfarin with Low-Molecular-Weight Heparin After Total Hip Arthroplasty\*\*

| Study                                       | Rate of Proximal Deep Venous Thrombosis* |         | Rate of Pulmonary Embolism* |         | Rate of Major Bleeding Episodes* |         |
|---------------------------------------------|------------------------------------------|---------|-----------------------------|---------|----------------------------------|---------|
|                                             | Result (%)                               | P Value | Result (%)                  | P Value | Result (%)                       | P Value |
| Hull et al. <sup>21</sup>                   |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to INR 2.0-3.0)             | 3.8 (13/340)                             |         | 0 (0/397)                   |         | 1.5 (6/397)                      |         |
| Fragmin (75 IU/kg daily)                    | 4.8 (16/332)                             |         | 0.3 (1/398)                 |         | 2.8 (11/398)                     |         |
| Hamulyak et al. <sup>53</sup>               |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to INR 2.0-3.0)             | 5.8 (15/257)                             |         | NA                          |         | 2.8 (8/342)                      |         |
| Nadroparine (60 IU/kg daily)                | 6.5 (17/260)                             |         | NA                          |         | 1.5 (5/330)                      |         |
| RD Heparin Arthroplasty Group <sup>28</sup> |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to INR 1.5-3.0)             | 6.3 (11/174)                             |         | 0 (0/174)                   |         | NA                               |         |
| RD heparin (90 IU/kg once daily)            | 7.0 (12/171)                             | 0.82    | 0 (0/171)                   |         | NA                               |         |
| RD heparin (50 IU/kg twice daily)           | 2.8 (5/178)                              | 0.070   | 0 (0/178)                   |         | NA                               |         |
| Francis et al. <sup>54</sup>                |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to IRN of 2.5)              | 8.4 (16/190)                             |         | NA                          |         | 1.4 (4/279)                      |         |
| Fragmin (5000 IU daily)                     | 5.0 (10/192)                             | 0.185   | NA                          |         | 2.2 (6/271)                      |         |
| Colwell et al. <sup>23</sup>                |                                          |         |                             |         |                                  |         |
| Enoxaparin (30 mg twice daily)              | 2.6 (40/1516)#                           |         | 0.4 (6/1516)                |         | 0.6 (9/1516)                     |         |
| Warfarin (dosed to INR 2.0-3.0)             | 2.9 (44/1495)#                           |         | 0.6 (9/1495)                |         | 0.3 (4/1495)                     |         |

INR= International Normalized Ratio, IU= International Factor Xa Inhibitory Units, and kg=kilogram.. \*The values are given as the percentage of patients, with the number affected divided by the total number in parentheses. P values are given if they were reported. IU/kg= international units/kilogram. #Deep Venous Thrombosis rates reported are symptomatic DVTs. \*\*Modified from: Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005 Sep;87(9):2097-112.

**Appendix II** Summary of Results from Multiple Randomized Clinical Trials Comparing Warfarin with Low-Molecular-Weight Heparin After Total Knee Arthroplasty\*\*

| Study                                       | Rate of Proximal Deep Venous Thrombosis* |         | Rate of Pulmonary Embolism* |         | Rate of Major Bleeding Episodes* |         |
|---------------------------------------------|------------------------------------------|---------|-----------------------------|---------|----------------------------------|---------|
|                                             | Result (%)                               | P Value | Result (%)                  | P Value | Result (%)                       | P Value |
| Hull et al. <sup>21</sup>                   |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to INR 2.0-3.0)             | 12.3 (34/277)                            |         | 0.3 (1/324)                 |         | 0.9 (3/324)                      |         |
| Fragmin (75 IU/kg daily)                    | 7.8 (20/258)                             |         | 0 (0/317)                   |         | 2.8 (9/317)                      |         |
| RD Heparin Arthroplasty Group <sup>28</sup> |                                          |         |                             |         |                                  |         |
| Wafarin (dosed to INR 1.5-3.0)              | 10.2 (15/147)                            |         | 0.7 (1/147)                 |         | NA                               |         |
| RD heparin (90 IU/kg once daily)            | 4.7 (7/149)                              | 0.04    | 0.6 (1/149)                 |         | NA                               |         |
| RD heparin (50 IU/kg twice daily)           | 6.0 (9/150)                              | 0.004   | 0 (0/150)                   |         | NA                               |         |
| Leclerc et al. <sup>55</sup>                |                                          |         |                             |         |                                  |         |
| Warfarin (dosed to INR 2.0-3.0)             | 10.4 (22/211)                            | >0.2    | 0.9 (3/334)                 |         | 1.8 (6/334)                      | >0.2    |
| Enoxaparin (30 mg twice daily)              | 11.7 (24/206)                            |         | 0.3 (1/336)                 | >0.2    | 2.1 (7/336)                      |         |
| Fitzgerald et al. <sup>56</sup>             |                                          |         |                             |         |                                  |         |
| Wafarin (dosed to INR 2.0-3.0)              | 11.4 (20/176)                            |         | 0.6 (1/176)                 |         | 2.3 (4/176)                      | 0.04    |
| Enoxaparin (30 mg twice daily)              | 1.7 (3/173)                              | 0.002   | 0 (0/173)                   |         | 5.2 (9/173)                      |         |

IU/kg= International Factor Xa Inhibitory Units per kilogram, and INR= International Normalized Ratio. \*The values are given as the percentage of patients, with the number affected divided by the total number in parentheses. P values are given if they were reported. IU/kg= international units/kilogram. \*\*Modified from: Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. J Bone Joint Surg Am. 2005 Sep;87(9):2097-112.

## References

1. Lieberman JR, Cheng V, Cote MP. Pulmonary embolism rates following total hip arthroplasty with prophylactic anticoagulation: some pulmonary emboli cannot be avoided. *J Arthroplasty*. 2017 Mar;32(3):980-6. Epub 2016 Sep 28.
2. Cote MP, Chen A, Jiang Y, Cheng V, Lieberman JR. Persistent pulmonary embolism rates following total knee arthroplasty even with prophylactic anticoagulants. *J Arthroplasty*. 2017 Dec;32(12):3833-9. Epub 2017 Jul 5.
3. Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S, Ortel TL, Pauker SG, Colwell CW Jr. Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest*. 2012 Feb;141(2)(Suppl):e278S-325S.
4. Bayley E, Brown S, Bhamber NS, Howard PW. Fatal pulmonary embolism following elective total hip arthroplasty: a 12-year study. *Bone Joint J*. 2016 May;98-B(5):585-8.
5. Lieberman JR, Pensak MJ. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2013 Oct 2;95(19):1801-11.
6. Parvizi J, Ghanem E, Joshi A, Sharkey PF, Hozack WJ, Rothman RH. Does “excessive” anticoagulation predispose to periprosthetic infection? *J Arthroplasty*. 2007 Sep;22(6 Suppl 2):24-8. Epub 2007 Jul 26.
7. Mont MA, Jacobs JJ, Boggio LN, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, Yates AJ Jr, Watters WC 3rd, Turkelson CM, Wies JL, Donnelly P, Patel N, Sluka P; AAOS. Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. *J Am Acad Orthop Surg*. 2011 Dec;19(12):768-76.
8. Lieberman JR. American College of Chest Physicians evidence-based guidelines for venous thromboembolic prophylaxis: the guideline wars are over. *J Am Acad Orthop Surg*. 2012 Jun;20(6):333-5.
9. Eikelboom JW, Karthikeyan G, Fagel N, Hirsh J. American Association of Orthopedic Surgeons and American College of Chest Physicians guidelines for venous thromboembolism prevention in hip and knee arthroplasty differ: What are the implications for clinicians and patients? *Chest*. 2009 Feb;135(2):513-20.
10. Parvizi J, Ceylan HH, Kucukdurmaz F, Merli G, Tuncay I, Beverland D. Venous thromboembolism following hip and knee arthroplasty: the role of aspirin. *J Bone Joint Surg Am*. 2017 Jun 7;99(11):961-72.
11. Abdel MP, Berry DJ. Current practice trends in primary hip and knee arthroplasties among members of the American Association of Hip and Knee Surgeons: a long-term update. *J Arthroplasty*. 2019 Jul;34(7S):S24-7. Epub 2019 Feb 12.
12. Hood BR, Cowen ME, Zheng HT, Hughes RE, Singal B, Hallstrom BR. Association of aspirin with prevention of venous thromboembolism in patients after total knee arthroplasty compared with other anticoagulants: a noninferiority analysis. *JAMA Surg*. 2019 Jan 1;154(1):65-72.
13. Jameson SS, Charman SC, Gregg PJ, Reed MR, van der Meulen JH. The effect of aspirin and low-molecular-weight heparin on venous thromboembolism after hip replacement: a non-randomised comparison from information in the National Joint Registry. *J Bone Joint Surg Br*. 2011 Nov;93(11):1465-70.
14. Lieberman JR, Heckmann N. Venous thromboembolism prophylaxis in total hip arthroplasty and total knee arthroplasty patients: from guidelines to practice. *J Am Acad Orthop Surg*. 2017 Dec;25(12):789-98.
15. Pellegrini VD Jr, Eikelboom J, McCollister Evarts C, Franklin PD, Goldhaber SZ, Iorio R, Lambourne CA, Magaziner JS, Magder LS; Steering Committee of The PEPPER Trial. Selection bias, orthopaedic style: knowing what we don’t know about aspirin. *J Bone Joint Surg Am*. 2020 Apr 1;102(7):631-3.

16. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. *Lancet*. 2000 Apr 15;355(9212):1295-302.
17. Matharu GS, Kunutsor SK, Judge A, Blom AW, Whitehouse MR. Clinical effectiveness and safety of aspirin for venous thromboembolism prophylaxis after total hip and knee replacement: a systematic review and meta-analysis of randomized clinical trials. *JAMA Intern Med*. 2020 Mar 1;180(3):376-84.
18. Anderson DR, Dunbar M, Murnaghan J, Kahn SR, Gross P, Forsythe M, Pelet S, Fisher W, Belzile E, Dolan S, Crowther M, Bohm E, MacDonald SJ, Gofton W, Kim P, Zukor D, Pleasance S, Andreou P, Doucette S, Theriault C, Abianui A, Carrier M, Kovacs MJ, Rodger MA, Coyle D, Wells PS, Vendittoli PA. Aspirin or rivaroxaban for VTE prophylaxis after hip or knee arthroplasty. *N Engl J Med*. 2018 Feb 22;378(8):699-707.
19. Azboy I, Groff H, Goswami K, Vahedian M, Parvizi J. Low-dose aspirin is adequate for venous thromboembolism prevention following total joint arthroplasty: a systematic review. *J Arthroplasty*. 2020 Mar;35(3):886-92. Epub 2019 Oct 5.
20. Parvizi J, Huang R, Restrepo C, Chen AF, Austin MS, Hozack WJ, Lonner JH. Low-dose aspirin is effective chemoprophylaxis against clinically important venous thromboembolism following total joint arthroplasty: a preliminary analysis. *J Bone Joint Surg Am*. 2017 Jan 18;99(2):91-8.
21. Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D, Elliott CG, Panju A, Brant R. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. *N Engl J Med*. 1993 Nov 4;329(19):1370-6.
22. Hull RD, Pineo GF, Francis C, Bergqvist D, Fellenius C, Soderberg K, Holmqvist A, Mant M, Dear R, Baylis B, Mah A, Brant R; North American Fragmin Trial Investigators. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double-blind, randomized comparison. *Arch Intern Med*. 2000 Jul 24;160(14):2208-15.
23. Colwell CW Jr, Collis DK, Paulson R, McCutchen JW, Bigler GT, Lutz S, Hardwick ME. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty. Evaluation during hospitalization and three months after discharge. *J Bone Joint Surg Am*. 1999 Jul;81(7):932-40.
24. Barnes GD. Predicting the quality of warfarin therapy: reframing the question. *Thromb Haemost*. 2019 Apr;119(4):509-11. Epub 2019 Feb 22.
25. Rondon AJ, Goswami K, Tan TL, Shohat N, Parvizi J. Majority of total joint arthroplasties are subtherapeutic on warfarin at time of discharge: another reason to avoid warfarin as a venous thromboembolism prophylaxis? *J Arthroplasty*. 2018 Sep;33(9):2787-91. Epub 2018 May 3.
26. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Anderson JL, Li J, Rodriguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple B, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of low-intensity vs standard-intensity warfarin prophylaxis on venous thromboembolism or death among patients undergoing hip or knee arthroplasty: a randomized clinical trial. *JAMA*. 2019 Sep 3;322(9):834-42.
27. Gage BF, Bass AR, Lin H, Woller SC, Stevens SM, Al-Hammadi N, Li J, Rodríguez T Jr, Miller JP, McMillin GA, Pendleton RC, Jaffer AK, King CR, Whipple BD, Porche-Sorbet R, Napoli L, Merritt K, Thompson AM, Hyun G, Anderson JL, Hollomon W, Barrack RL, Nunley RM, Moskowitz G, Dávila-Román V, Eby CS. Effect of genotype-guided warfarin dosing on clinical events and anticoagulation control among patients

- undergoing hip or knee arthroplasty: the GIFT randomized clinical trial. *JAMA*. 2017 Sep 26;318(12):1115-24.
28. RD Heparin Arthroplasty Group. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. *J Bone Joint Surg Am*. 1994 Aug;76(8):1174-85.
29. Whang PG, Lieberman JR. Low-molecular-weight herapin [sic]. *J Am Acad Orthop Surg*. 2002 Sep-Oct;10(5):299-302.
30. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. *Chest*. 2004 Sep;126(3)(Suppl):311S-37S.
31. Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. *N Engl J Med*. 2008 Jun 26;358(26):2765-75.
32. Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S; RECORD2 Investigators. Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. *Lancet*. 2008 Jul 5;372(9632):31-9. Epub 2008 Jun 24.
33. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosensch N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. *N Engl J Med*. 2008 Jun 26;358(26):2776-86.
34. Turpie AG, Lassen MR, Davidson BL, Bauer KA, Gent M, Kwong LM, Cushner FD, Lotke PA, Berkowitz SD, Bandel TJ, Benson A, Misselwitz F, Fisher WD; RECORD4 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial. *Lancet*. 2009 May 16;373(9676):1673-80. Epub 2009 May 4.
35. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Hornick P; ADVANCE-2 investigators. Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. *Lancet*. 2010 Mar 6;375(9717):807-15.
36. Lassen MR, Gallus A, Raskob GE, Pineo G, Chen D, Ramirez LM; ADVANCE-3 Investigators. Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. *N Engl J Med*. 2010 Dec 23;363(26):2487-98.
37. Lassen MR, Raskob GE, Gallus A, Pineo G, Chen D, Portman RJ. Apixaban or enoxaparin for thromboprophylaxis after knee replacement. *N Engl J Med*. 2009 Aug 6;361(6):594-604.
38. Eriksson BI, Dahl OE, Rosensch N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR; RE-NOVATE Study Group. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. *Lancet*. 2007 Sep 15;370(9591):949-56.
39. Eriksson BI, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Schnee JM, Friedman RJ; RE-NOVATE II Study Group. Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II\*). A randomised, double-blind, non-inferiority trial. *Thromb Haemost*. 2011 Apr;105(4):721-9. Epub 2011 Jan 12.
40. Eriksson BI, Dahl OE, Rosensch N, Kurth AA, van Dijk CN, Frostick SP, Kålebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. *J Thromb Haemost*. 2007 Nov;5(11):2178-85.

41. Ginsberg JS, Davidson BL, Comp PC, Francis CW, Friedman RJ, Huo MH, Lieberman JR, Muntz JE, Raskob GE, Clements ML, Hantel S, Schnee JM, Caprini JA; RE-MOBILIZE Writing Committee. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. *J Arthroplasty*. 2009 Jan;24(1):1-9. Epub 2008 Apr 14.
42. Colwell CW Jr, Froimson MI, Mont MA, Ritter MA, Trousdale RT, Buehler KC, Spitzer A, Donaldson TK, Padgett DE. Thrombosis prevention after total hip arthroplasty: a prospective, randomized trial comparing a mobile compression device with low-molecular-weight heparin. *J Bone Joint Surg Am*. 2010 Mar;92(3):527-35.
43. Caprini JA, Arcelus JJ, Reyna JJ. Effective risk stratification of surgical and nonsurgical patients for venous thromboembolic disease. *Semin Hematol*. 2001 Apr;38(2)(Suppl 5):12-9.
44. Parvizi J, Huang R, Rezapoor M, Bagheri B, Maltenfort MG. Individualized risk model for venous thromboembolism after total joint arthroplasty. *J Arthroplasty*. 2016 Sep;31(9)(Suppl):180-6. Epub 2016 Mar 17.
45. Nam D, Nunley RM, Johnson SR, Keeney JA, Clohisy JC, Barrack RL. Thromboembolism prophylaxis in hip arthroplasty: routine and high risk patients. *J Arthroplasty*. 2015 Dec;30(12):2299-303. Epub 2015 Jul 2.
46. Bohl DD, Maltenfort MG, Huang R, Parvizi J, Lieberman JR, Della Valle CJ. Development and validation of a risk stratification system for pulmonary embolism after elective primary total joint arthroplasty. *J Arthroplasty*. 2016 Sep;31(9)(Suppl):187-91. Epub 2016 Mar 17.
47. Parvizi J. DVT prophylaxis: risk stratification solutions. *Orthopaedic Proceedings*. 2018;99-B(SUPP\_7):40.
48. Douketis JD, Spyropoulos AC, Kaatz S, Becker RC, Caprini JA, Dunn AS, Garcia DA, Jacobson A, Jaffer AK, Kong DF, Schulman S, Turpie AG, Hasselblad V, Ortel TL; BRIDGE Investigators. Perioperative bridging anticoagulation in patients with atrial fibrillation. *N Engl J Med*. 2015 Aug 27;373(9):823-33. Epub 2015 Jun 22.
49. Thrombosis Canada. Anticoagulation in Patients Requiring Antiplatelet Therapy. 2020. Accessed 2020 Dec 1. [https://thrombosiscanada.ca/wp-uploads/uploads/2021/01/41.-Anticoagulation-in-patients-requiring-antiplatelet-therapy\\_05August2020.pdf](https://thrombosiscanada.ca/wp-uploads/uploads/2021/01/41.-Anticoagulation-in-patients-requiring-antiplatelet-therapy_05August2020.pdf)
50. Thrombosis Canada. Warfarin. 2020. Accessed 2020 Dec 1. [https://thrombosiscanada.ca/wp-content/uploads/2020/04/Warfarin\\_27April2020.pdf](https://thrombosiscanada.ca/wp-content/uploads/2020/04/Warfarin_27April2020.pdf)
51. Jacob AK, Hurley SP, Loughran SM, Wetsch TM, Trousdale RT. Continuing clopidogrel during elective total hip and knee arthroplasty: assessment of bleeding risk and adverse outcomes. *J Arthroplasty*. 2014 Feb;29(2):325-8. Epub 2013 Jul 12.
52. Nandi S, Aghazadeh M, Talmo C, Robbins C, Bono J. Perioperative clopidogrel and postoperative events after hip and knee arthroplasties. *Clin Orthop Relat Res*. 2012 May;470(5):1436-41. Epub 2012 Mar 9.
53. Hamulyak K, Lensing AW, van der Meer J, Smid WM, van Ooy A, Hoek JA. Subcutaneous low-molecular weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement? Fraxiparine Oral Anticoagulant Study Group. *Thromb Haemost*. 1995 Dec;74(6):1428-31. Epub 1995/12/01.
54. Francis CW, Pellegrini VD, Jr., Totterman S, Boyd AD, Jr., Marder VJ, Liebert KM, Stulberg BN, Ayers DC, Rosenberg A, Kessler C, Johanson NA. Prevention of deep-vein thrombosis after total hip arthroplasty. Comparison of warfarin and dalteparin. *J Bone Joint Surg Am*. 1997 Sep;79(9):1365-72. Epub 1997/10/06.
55. Leclerc JR, Geerts WH, Desjardins L, Laflamme GH, L'Esperance B, Demers C, Kassis J, Cruickshank M, Whitman L, Delorme F. Prevention of venous thromboembolism after knee arthroplasty. A randomized, double-blind trial comparing enoxaparin with warfarin. *Ann Intern Med*. 1996 Apr 1;124(7):619-26. Epub 1996/04/01.
56. Fitzgerald RH, Jr., Spiro TE, Trowbridge AA, Gardiner GA, Jr., Whitsett TL, O'Connell MB, Ohar JA, Young TR, Enoxaparin Clinical Trial G. Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. *J Bone Joint Surg Am*. 2001 Jun;83(6):900-6. Epub 2001/06/16.

57. Lieberman JR, Hsu WK. Prevention of venous thromboembolic disease after total hip and knee arthroplasty. *J Bone Joint Surg Am*. 2005 Sep;87(9):2097-112. Epub 2005/09/06.